| |
IQVIA experts evaluate epidemiological variances for indication-specific distribution to better-inform diversity goals for clinical trials. Download the white paper.
|
|
| By Angus Liu Singapore set out on a journey to become a biotech hub back in 2000, when local government made biomedical research the “fourth pillar” of the city state’s economy. With the sudden collapse of Tessa Therapeutics, Singapore is still waiting for its big biotech success story. |
|
|
|
By Fraiser Kansteiner Friday, the U.S. FDA gave the green light to zuranolone. Now going by the commercial moniker Zurzuvae, the partners’ drug represents the first and only oral treatment for women with PPD, which affects some 500,000 patients in the U.S. each year, according to Biogen and Sage. |
By James Waldron Sage Therapeutics is preparing to reduce its head count and pipeline in response to the FDA’s rejection of a Biogen-partnered drug as a treatment for major depressive disorder. |
By Angus Liu As Pfizer eyes possible cost cuts, its COVID vaccine partner BioNTech is “carefully watching” its spending, the German company’s finance chief Jens Holstein said Monday. |
|
Wednesday, September 6, 2023 | 2:00 PM ET / 11:00 AM PT Attendees will learn about the latest tools for interacting with medical images, how to guide readers through labeling workflows, and streamlining adjudication and data standardization. Discussions will include real-world use cases of how pharma companies are enhancing AI development by optimizing reader workflows. Register now.
|
|
By Gabrielle Masson After a bout of bad luck, Vistagen’s social anxiety spray has puffed out a phase 3 win—data that have sent the biotech's stock soaring. |
By Kevin Dunleavy When Amgen launched the first biosimilar to compete with AbbVie’s Humira in the U.S., the company looked forward to six months of exclusivity in competing one-on-one against the immunology powerhouse. But Thursday, Amgen reported second-quarter sales of just $19 million for Amjevita, a 63% drop sequentially. |
By Andrea Park Neuralink, the Elon Musk-founded company developing an implant he’s described as “a Fitbit in your skull,” recently announced that it had gotten the go-ahead from the FDA to begin clinical trials—and now, it has secured extra funding to see the studies through. |
By Zoey Becker Under the agreement, Ginkgo will seek to streamline production and boost output through cell engineering and protein characterization, the companies said in a Monday release. |
By Helen Floersh The company is tripling down on its Alzheimer’s franchise, rounding out its tau-focused pipeline with a gene therapy aimed at amyloid-beta plaques. |
By Nick Paul Taylor The antibody-drug conjugate (ADC) market is emerging as one of the most competitive areas in pharma, with companies such as AstraZeneca, Gilead and Pfizer investing billions into the space. Amid the vying for commercial position, analysts at GlobalData expect Daiichi Sankyo to dominate the space through 2029. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we discuss left-handedness and its significance in neurodevelopmental and psychiatric disorder research. |
|
|---|
|
|
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WebinarWatch this webinar to learn how an end-to-end platform can simplify the systems landscape and help facilitate cross-functional collaboration, accelerate clinical development and centralize data for efficacious decision-making. Sponsored by: Cognizant |
| WhitepaperLearn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
